{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/deep-vein-thrombosis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"c5e88810-6d89-56ef-9120-966cbdac34da","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field e5848f0d-f594-46ca-8896-14f0d12885de --><h2>Changes</h2><!-- end field e5848f0d-f594-46ca-8896-14f0d12885de -->","summary":null,"htmlStringContent":"<!-- begin item c627da86-4ed3-4f42-b22f-62d02bb35545 --><!-- begin field fd668aff-fd12-409b-bd3d-c7c9e1d43e18 --><p><strong>November 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>October 2020</strong> — minor update. The contraindications for dalteparin have been updated in line with the manufacturer's revised SPC.</p><p><strong>March 2020</strong> — minor update. The management section of this topic has been updated in line with the updated NICE guideline <em>Venous thromboembolic diseases: diagnosis, management and thrombophilia testing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/references/\">NICE, 2020</a>].</p><p><strong>November 2019 to January 2020</strong> — reviewed. A literature search was conducted in November 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. </p><!-- end field fd668aff-fd12-409b-bd3d-c7c9e1d43e18 --><!-- end item c627da86-4ed3-4f42-b22f-62d02bb35545 -->","topic":{"id":"c1b45e75-436b-56a1-a385-f8422d715e82","topicId":"a4df6bb3-1690-4ec4-9cba-0dcff60cc7ef","topicName":"Deep vein thrombosis","slug":"deep-vein-thrombosis","lastRevised":"Last revised in November 2020","chapters":[{"id":"043e731c-3abf-53ee-a31d-8d884bd3bc70","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bf477005-0407-58ad-9621-2529440a1912","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0d6b5798-088f-5468-84b7-a93cfe9e70d4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c5e88810-6d89-56ef-9120-966cbdac34da","slug":"changes","fullItemName":"Changes"},{"id":"06d2c305-090e-5332-b7a1-b6be267bcd41","slug":"update","fullItemName":"Update"}]},{"id":"0e61afec-aecd-50f3-8f6d-ef8da1dc9003","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"acd9fd74-ef09-56e2-b4e4-65e22ddc6269","slug":"goals","fullItemName":"Goals"},{"id":"13b37b76-163e-58e7-9ed4-add17978eb23","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c283b01d-3860-51e0-bb61-d68a12c34e68","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6c0366d1-9980-5dc1-8946-44e5030bc691","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"707aca3b-1b4f-52aa-848d-6d44d4337f41","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b9c8c09-f068-59bc-ad89-ca508289d1b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"341b7f8d-b4d0-58b0-8198-4c563cb9f40e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b31fd103-9bbb-5216-ad96-7ce04f610584","slug":"definition","fullItemName":"Definition"},{"id":"f95afcb9-845a-579a-a5bd-b95f7163d1b9","slug":"incidence","fullItemName":"Incidence"},{"id":"fb6ff0cb-ba3b-5075-9e5e-52380bc0ecd3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b828ffa2-5a2d-5a7d-89c2-3b5ce4c27b07","slug":"complications","fullItemName":"Complications"}]},{"id":"837dc43f-aac0-51fa-af65-afb4b7a54467","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"699e0a9f-a13f-535b-91e2-967968d57b5e","slug":"when-to-suspect-dvt","fullItemName":"When to suspect DVT"},{"id":"e436c043-ce99-5fc5-b99e-deb107b997e9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9caf86d2-a390-5cb8-bcec-dd055468ba41","fullItemName":"Management","slug":"management","subChapters":[{"id":"edd98243-d8d1-5402-a55c-9d8de8e68068","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"02795cd7-4068-5ef2-840c-914a96cfd71b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"15bc2153-6b1c-5a58-9c8d-25d9978f2dde","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"7e7201d1-4e56-53ec-95ac-c64ea70060e4","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"a5e9e695-9150-5486-8075-1fa6c8b75fba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06671f87-530c-52a1-800c-749cdb70cad7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"63cf38fe-dc13-5253-93e7-bb3da5b958a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"439fde91-9bb2-561f-8d66-de440bc5e387","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0f076b49-f0f3-597a-ba30-f5f3f414beae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5e81047f-a3c4-52f4-ad24-f951952ea809","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17391681-76bf-5417-9a9c-6e66245c631d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2cd34860-5410-5109-8de9-0227c8af1e62","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d6b5798-088f-5468-84b7-a93cfe9e70d4","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"50b0a865-ce34-53fb-9071-e192715e52bf","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 01afebaf-8d6d-4ce2-8096-b7c7c85b0aec --><h3>Previous changes</h3><!-- end field 01afebaf-8d6d-4ce2-8096-b7c7c85b0aec -->","summary":null,"htmlStringContent":"<!-- begin item f694d739-eb79-4dd6-8ede-6221382b81b4 --><!-- begin field 38c2572a-8a8c-4a3f-a86e-3e8579588664 --><p><strong>September 2018</strong> — minor update. Details of a randomised placebo-controlled trial which informed the update to the NICE guideline CG144, have been added to the basis for recommendation in the section Follow up for DVT.</p><p><strong>January 2018</strong> — minor update. Changes made to recommendations on the use of elastic graduated compression stockings to prevent post-thrombotic syndrome or VTE recurrence after a proximal DVT as per updates to NICE guideline CG144.</p><p><strong>December 2013</strong> — minor update. Deleted duplicated text and removed reference to prescriptions in the CKS topic on Compression stockings.</p><p><strong>April 2013 </strong>— reviewed. A literature search was conducted in March 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Based on the new NICE guideline: <em>Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing</em>, the recommendations for the management of suspected deep vein thrombosis has been revised to include the option of giving an interim 24-hour dose of parenteral anticoagulant if a proximal leg vein ultrasound scan cannot be carried out within 4 hours of being requested. See <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/management/management/#management-of-suspected-dvt\">Management of suspected DVT</a> for more information.</p><p><strong>July 2011 </strong>— minor update. All references to the British Committee for Standards in Haematology (BCSH) guideline on oral anticoagulation with warfarin have been updated to reflect the latest guideline. Issued in September 2011.</p><p><strong>June 2010 </strong>— minor update. The recommendation on the class of compression stockings to use to prevent the recurrence of deep vein thrombosis, or the development of post-thrombotic syndrome, has been updated. Issued June 2010.</p><p><strong>January 2010 </strong>— minor update. Minor text change to the <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/management/management/#basis-for-recommendation-164\">Basis for recommendation</a> section on <a class=\"topic-reference internal-reference\" href=\"/topics/deep-vein-thrombosis/management/management/#management-of-suspected-dvt\">Management of suspected DVT</a>, including clarification of why CKS recommends use of the Wells Clinical Prediction Rule in preference to other clinical prediction rules (when D-dimer testing is available in primary care). Issued in January 2010.</p><p><strong>December 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>June 2007 </strong>— updated to include a link to the recent <em>Patient Safety Alert </em>from the National Patient Safety Agency (NPSA) on actions that can make anticoagulant therapy safer. Advice from the British Committee for Standards in Haematology on the management of patients on oral anticoagulants requiring dental surgery also included. Advice on managing interactions with warfarin also reformatted. Issued in June 2007.</p><p><strong>July 2006 </strong>— minor update to include advice from the Commission on Human Medicines (CHM) regarding the potential interaction between warfarin and glucosamine. Issued in July 2006.</p><p><strong>October to December 2005 </strong>— reviewed. Validated in March 2006 and issued in May 2006.</p><p><strong>July 2005 </strong>— minor update to include prescribing information for compression stockings. Issued in July 2005.</p><p><strong>July 2002 </strong>— reviewed. A scenario on <em>Advice on risk of travel-related deep vein thrombosis </em>was added. Validated in October 2002 and issued in December 2002.</p><p><strong>February 2001 </strong>— reviewed to incorporate the recommendations of the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Antithrombotic Therapy </em>(1999).</p><p><strong>February 1999 </strong>— written. Validated in April 1999 and issued in August 1999.</p><!-- end field 38c2572a-8a8c-4a3f-a86e-3e8579588664 --><!-- end item f694d739-eb79-4dd6-8ede-6221382b81b4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}